Adverse reactions of selective serotonin reuptake inhibitors: Reports from a spontaneous reporting system

Drug Safety

Volumn 20, Issue 3, 1999, Pages 277-287

  Spigset, Olav ^a,b  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; AKATHISIA; ANXIETY NEUROSIS; ARTICLE; BLOOD DISEASE; BRADYCARDIA; CONFUSION; COUGHING; DEPRESSION; DIARRHEA; DYSKINESIA; ENDOCRINE DISEASE; EUPHORIA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HALLUCINATION; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPONATREMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MANIA; NAUSEA; OBESITY; OBSESSION; PANIC; PARESTHESIA; PARKINSONISM; PRIORITY JOURNAL; RASH; SEIZURE; SEROTONIN SYNDROME; SWEDEN; URTICARIA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; DATA COLLECTION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SWEDEN;

EID: 0033051316     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920030-00007     Document Type: Article

References (20)

1. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7
2. Borg S, Brodin K. Antidepressant drugs. In: Dukes MNG, editor. Meyler's side effects of drugs. 12th ed. Amsterdam: Elsevier, 1992: 30-78
3. Spigset O, Hedenmalm K, Dahl M-L, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2CI9 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96: 379-84
4. Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone excretion (SIADH) induced by psychotropic drugs. Drug Saf 1995; 12: 209-225
5. Sporer KA. The serotonin syndrome. Drug Saf 1995; 13: 94-104
6. WHO collaborating centre for drug statistics methodology. Guidelines for defined daily doses (DDD). Oslo: WHO collaborating centre for drug statistics methodology, 1991: 76
7. WHO collaborating centre for drug statistics methodology. Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDD) for plain substances. Oslo: WHO collaborating centre for drug statistics methodology, 1997
8. Wiholm B-E, Olsson S, Moore N, et al. Spontaneous reporting systems outside the United Sates. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley and Sons, 1994: 139-55
9. Dukes MNG. The importance of adverse reactions in drug regulation. Drug Saf 1990; 5: 3-6
10. Rawlins MD. Spontaneous reporting of adverse drug reactions. Br J Clin Pharmacol 1988; 26: 1-5
11. Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16: 373-8
12. Haffmans PMJ, Timmerman L, Hoogduin CAL, and the LUCIFER group. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996; II: 157-64
13. De Vilde J, Spiers R, Mertens C, et al. A double blind, comparative, multicentre study comparing paroxetine with fluoxeline in depressed patients. Acta Psychiatr Scand 1993; 87: 141-5
14. Pinder RM. Mianserin: pharmacological and clinical correlates. Nord J Psychiatr 1991; 45 Suppl. 24: 13-26
15. Stahl MMS, Lindquist M, Petterson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-9
16. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-6
17. Mitchelson F. Pharmacological agents affecting emesis: a review (part I). Drugs 1992; 43: 295-315
18. Lance W, Lambert GA, Goadsby PJ et al. 5-hydroxytryptamine and its putative aetiological involvement in migraine. Cephalalgia 1989; 9 Suppl. 9: 7-13
19. Riedel W, van Praag HM. Avoiding and managing anticholinergic effects of antidepressants. CNS Drugs 1995; 3: 245-59
20. Bertilsson L, Dahl M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 3: 200-23